BANGALORE and FOSTER CITY, California, October 4, 2016 /PRNewswire/ --
MedGenome today announced that it has purchased the Illumina Hiseq X Ten platform to fuel its genomic research services capability and capacity. MedGenome joins a small number of global players in the genomics research space, and the first one in South-East Asia, to own one of these high throughput Illumina sequencing platforms.
(Logo: http://photos.prnewswire.com/prnh/20160112/784044 )
"We are passionate about improving human health through use of genomics research and insights," said Mr. Sam Santhosh, Chairman and Global CEO, MedGenome." We will have these machines operational in India and the US by next month and will be looking forward to collaborating with various large-scale genomic projects in the region and abroad."
With its high throughput and unprecedented low price per genome, the HiSeq X Ten makes population-scale whole-genome sequencing (WGS) an affordable reality. The technology is bringing down the price of Whole Genome and Whole Genome Methylation sequencing to one-third of the current cost. Affordable sequencing could also have a huge impact in diagnostics.
"The HiSeq X Ten System is the first and only platform to break the barrier of high cost for high-quality human whole genome sequencing," said Tim Orpin, Vice President Asia Pacific, Illumina. "We are happy to partner with MedGenome to drive the genomics revolution in India and continue to work towards our vision of unlocking the power of the genome."
The possibilities of the large-scale genetic sequencing projects and the innovative genomic research that it can enable to better understand complex human diseases is well understood by the research community. The HiSeq X10 machines continue to break down barriers in traditional sequencing technologies, and in redefining the cost of whole-genome sequencing. It facilitates the path breaking research that is taking place across the world in the form of population-scale genome sequencing projects. This high performing system promises to accelerate a deeper understanding of genetic disorders to allow us to find ways to better tackle them.
About MedGenome
MedGenome (http://www.medgenome.com) is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual's genome. MedGenome is a market leader for genomic diagnostics in South Asia and a leading provider of genomics research services globally. MedGenome offers genomics solutions in cancer immunotherapy and diabetes and works with various commercial and academic researchers globally on genomic research projects. It is also a founding member of GenomeAsia 100K initiative to sequence 100,000 genomes in South, North and East Asia.
MedGenome is a global genomics firm with presence in USA, India and Singapore. Our NGS lab in Foster City, California is ISO 15189 compliant, CLIA certified and CAP accredited. Our NGS lab in Bangalore, India is the highest throughput facility in South-East Asia.
Forward-looking Statements:
This document contains certain forward-looking statements, other than the statements of research facts contained in this press release are forward looking statements. Terms such as "believe", "estimate", "anticipate", "plan", "predict", "may", "hope", "can", "will", "should", "expect", "intend", "is designed to", "with the intent", "potential", the negative of these words or such other variations thereon or comparable terminology, may indicate forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements speak only as of the date of this press release. The events and circumstances reflected in MedGenome's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, MedGenome does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Media Contact:
Jeevarekha
[email protected]
+91-9886787900
Concept Public Relations
Share this article